These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The genetics of systemic sclerosis: an update. Romano E; Manetti M; Guiducci S; Ceccarelli C; Allanore Y; Matucci-Cerinic M Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S75-86. PubMed ID: 21586222 [TBL] [Abstract][Full Text] [Related]
28. Evaluating microangiopathy in systemic sclerosis: what have we learnt and what is left to discover? Cutolo M; Sulli A; Smith V Expert Rev Clin Immunol; 2011 Jul; 7(4):395-7. PubMed ID: 21790279 [No Abstract] [Full Text] [Related]
29. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Sunderkötter C; Riemekasten G Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831 [TBL] [Abstract][Full Text] [Related]
30. Fibroblast and endothelial apoptosis in systemic sclerosis. Jun JB; Kuechle M; Harlan JM; Elkon KB Curr Opin Rheumatol; 2003 Nov; 15(6):756-60. PubMed ID: 14569206 [TBL] [Abstract][Full Text] [Related]
31. Systemic sclerosis: a collagen or microvascular disease? Jayson MI Br Med J (Clin Res Ed); 1984 Jun; 288(6434):1855-7. PubMed ID: 6428575 [No Abstract] [Full Text] [Related]
32. Lung involvement in systemic sclerosis. Silver RM; Miller KS Rheum Dis Clin North Am; 1990 Feb; 16(1):199-216. PubMed ID: 2406808 [TBL] [Abstract][Full Text] [Related]
33. Vascular disease in progressive systemic sclerosis (scleroderma). Norton WL; Nardo JM Ann Intern Med; 1970 Aug; 73(2):317-24. PubMed ID: 4916764 [No Abstract] [Full Text] [Related]
35. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Kräling BM; Maul GG; Jimenez SA Pathobiology; 1995; 63(1):48-56. PubMed ID: 7546275 [TBL] [Abstract][Full Text] [Related]
36. Scleroderma: pathogenic factors and current management. Penny R Aust N Z J Med; 1978; 8 Suppl 1():143-8. PubMed ID: 365159 [TBL] [Abstract][Full Text] [Related]
37. Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis. Honda N; Jinnin M; Kajihara I; Makino T; Fukushima S; Ihn H Br J Dermatol; 2010 Oct; 163(4):776-80. PubMed ID: 20491763 [TBL] [Abstract][Full Text] [Related]
38. Body composition and microvascular damage in systemic sclerosis patients. Gigante A; Rosato E; Muscaritoli M J Endocrinol Invest; 2021 Jan; 44(1):205-206. PubMed ID: 32683616 [No Abstract] [Full Text] [Related]
39. The vascular, inflammatory, and fibrotic components in scleroderma skin. Fleischmajer R; Perlish JS Monogr Pathol; 1983; 24():40-54. PubMed ID: 6350857 [No Abstract] [Full Text] [Related]
40. Oxidative stress, microvascular dysfunction, and scleroderma: an association with potential therapeutic implications, a commentary on "Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis". Chung CP; Avalos I; Stein CM Free Radic Biol Med; 2006 May; 40(10):1698-9. PubMed ID: 16678008 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]